

**BioServ Corporation Engages Services of Goldman-Collins Associates to
establish Five Year Growth Strategy**

San Diego, CA, 17th January 2011 – BioServ Corporation, a leading aseptic and device contract manufacturing, cold chain and logistics outsourcing services to the pharmaceutical and biotech industry has pleased to announce that it has engaged the services of Goldman Collins Associates, LLC., to assess the capabilities of the corporation and to develop a five year growth plan and strategy

Martin Sellers, the General Manager of BioServ Corporation commented: “We are delighted to have Goldman Collins working with us. They have a proven track record and extensive knowledge of the North American and Canadian pharmaceutical and biotechnology markets. I am convinced that Goldman Collins will make a significant contribution to BioServ’s future growth as we continue to enhance our contract manufacturing and logistics services.”

BioServ Corporation manufactures, packages, and distributes a broad range of aseptic and device products and formulations for its pharmaceutical customers from clinical trials through commercialization.

BioServ Corporation is based in San Diego, California, serves small to large corporations world wide in the biotechnology, pharmaceutical, diagnostic, and medical device industries. Its aseptic area has multiple clean room suites offering Class 10,000 (Class 7 or Class C) formulation rooms and Class 100 (Class 5 or Class A) filling areas This facility is FDA licensed for drugs and medical devices and ISO 13485:2003 certified for medical device manufacturing.

-Ends-

Contact:

Martin Sellers
General Manager
BioServ Corporation
Tel 858-450-3123
Martin.Sellers@NextPharma-US.com

Ronald W. Collins
Principal
Goldman Collins Associates
Tel 603-744-1048
RCollins@GoldmanCollins.com

About Goldman-Collins Associates

Goldman-Collins Associates is an International Business Consulting company formed in 1999. It specializes in mergers, acquisitions, business development, company start-ups, and business planning and analysis. Since June 2000, Goldman-Collins Associates has been responsible for starting two domestic companies and one international company; and has obtained major funding and managed a major expansion for a biotechnology company.

Ronald W. Collins, a scientist by training, served as a Vice President of the Polaroid Corporation and later as President and CEO of Transtec Manufacturing Systems. In 1999, he established Goldman-Collins Associates as international consultants to high technology industries. For the past four years Goldman Collins has developed a focus on the biotechnology and pharmaceutical industry.